Key result
Dysregulation of immune cells occurs in the early stages of NAFLD, and targeting these cells may represent an effective therapeutic strategy for NASH.
Why the study?
Specific and effective treatments for NASH are lacking, and understanding immune cell alterations during NAFLD pathogenesis may aid in developing new therapies.
Understanding immune cell dysregulation in NAFLD/NASH pathogenesis may help identify novel therapeutic targets.
Hypothesis-generating for immune-targeted NASH therapies; prospective trials needed before any clinical consideration.
The prevalence of non-alcoholic fatty liver disease (NAFLD) increases rapidly in recent decades. NAFLD has become a major public health problem in China and the whole world, and it is considered as the main cause for the chronic liver diseases. However, there is still not specific and effective treatment for non-alcoholic steatohepatitis (NASH), the advanced form of NAFLD. The inflammation in the liver is the hallmark of NASH. Actually, the dysregulation of immune cells happened in the early stage of NAFLD. Targeting immune cells in the liver may represent one of the effective ways for NASH treatment. A better understanding of the change of immune cells in the pathogenesis of NAFLD will be very helpful for developing new treatments for NAFLD and NASH. Here we summarized how the immune cells were affected in different stages of NAFLD and how these immune cells contributed to the development of NAFLD.
No takes yet. Share an insight, caveat, or question.
Dechun Feng (2020) conducted a review in Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Immune cell alteration was evaluated. Dysregulation of immune cells occurs in the early stages of NAFLD, and targeting these cells may represent an effective therapeutic strategy for NASH.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: